Role of Combined Use of Adiponectin and hsCRP in Cardiovascular Risk in Pediatric Neurogenic Bladder

Joanna Bagińska-Chyży1, Alicja Szymańska1, Agata Korzeniecka-Kozerska1

  • 1Department of Pediatrics and Nephrology, Medical University of Białystok, 17 Waszyngton Str., 15-274 Białystok, Poland.

PubMed

Insights

Children with neurogenic bladder (NB) show elevated high-sensitivity C-reactive protein (hsCRP), indicating increased cardiovascular disease (CVD) risk. Adiponectin levels are also altered, suggesting complex metabolic links to CVD in this population.

Area of Science:

  • Pediatric Cardiology
  • Neurology
  • Biochemistry

Background:

  • Myelomeningocele (MMC) is a severe spina bifida form leading to lower limb paralysis and neurogenic bladder (NB).
  • These conditions can predispose to nutritional disorders and future cardiovascular diseases (CVDs).
  • High-sensitivity C-reactive protein (hsCRP) is a CVD marker, while adiponectin has anti-inflammatory properties.

Purpose of the Study:

  • To evaluate cardiovascular disease risk in children with neurogenic bladder.
  • To compare serum levels of adiponectin, hsCRP, and lipid profiles between children with NB and a control group.

Main Methods:

  • Prospective clinical study of 87 children (67 NB, 20 controls).
  • Collected data: sex, age, anthropometrics (BMI), spinal lesion level, activity (Hoffer's scale).
  • Assessed lipid profiles, hsCRP, and adiponectin via standard tests and ELISA kits.

Main Results:

  • Statistically significant differences in adiponectin and hsCRP levels between NB and control groups.
  • Positive correlation between hsCRP and BMI; negative correlation between adiponectin and BMI.
  • Highest hsCRP concentrations observed in MMC patients with thoracic lesions and non-walkers.

Conclusions:

  • Elevated hsCRP suggests increased cardiovascular risk in children with neurogenic bladder.
  • Altered adiponectin levels indicate a complex association with cardiovascular risk, potentially involving additional metabolic pathways.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
223
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
Neural Regulation of Blood Pressure01:18

Neural Regulation of Blood Pressure

The neural regulation of blood pressure involves intricate interactions between the autonomic nervous system (ANS) and cardiovascular system, ensuring adequate perfusion of tissues. This regulation primarily occurs through baroreceptor and chemoreceptor reflexes, involving both short-term and long-term mechanisms.
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
3.5K